(Boursier.com) — Amoeba did not achieve any turnover during the 2023 financial year. Subsidies are up +44% compared to the previous financial year. They mainly consist of the Research Tax Credit and highlight the efforts made by the company in terms of research and development on the biocontrol application during the year 2023.
The current operating profit stands at -6.64 million euros as of December 31, 2023 (-5.84 ME as of December 31, 2022).
The net result stands at -14.3 ME (-8.02 ME as of December 31, 2022). Excluding non-recurring asset depreciation items, the 2023 result would be -6.7, an improvement of 1.32 ME compared to the previous year.
The company’s cash position as of December 31, 2023 amounts to €519 thousand (€5.53 million as of December 31, 2022). Shareholders’ equity is -3.9 ME (8.2 ME as of December 31, 2022). The Company’s financial debt amounts to -4.92 ME (-2.36 ME KEUR as of December 31, 2022). It consists of debts linked to the Nice & Green bond loan (3.66 ME), rental obligations (748 kE) and the repayable advance granted by Bpi France (514 kE).
Quoting…
Governance
During the Board of Directors meeting on March 28, Fabrice Plasson presented his resignation from his mandate as director. This resignation took effect at the end of the Council meeting. The Board of Directors thanks him “for his action during all his years of presence within the company and its governance bodies”.
Outlook
At the closing date of the accounts, Amoéba indicates that it has sufficient net working capital to meet its obligations and its cash flow needs until December 31, 2024. The company believes it can meet its commitments made to date.
©2024 Boursier.com